Since their development and widespread adoption in the late 1980s, proton pump inhibitors (PPI) have transformed the field of gastroenterology. Their high efficacy and favorable safety profiles have made them essential in the management of potentially life-threatening conditions, including peptic ulcer disease and upper gastrointestinal bleeding.

Despite their established role, PPI have been increasingly portrayed as harmful. Claims in both the scientific literature and general media have raised concerns about possible long-term adverse effects. This perception has become widespread, leading nearly 40% of individuals to discontinue PPI, most without informing their clinician, primarily because of the fear of side effects.

For clinicians, the growing disconnect between evidence and perceptions has practical consequences. Distinguishing between speculative associations, confirmed adverse effects, and inappropriate prescriptions is essential to ensure rational use and maintain patient confidence in effective therapy.

Associations Without Proven Causality

Much of the criticism directed at PPI in recent years has been based on retrospective studies, linking their use to outcomes such as dementia, fractures, kidney disease, and gastric cancer.

In most instances, these findings represent statistical associations rather than causal relationships and are strongly influenced by confounding factors, including advanced age, polypharmacy, and underlying comorbidities.

Their potent acid-suppressive effects are associated with structural and functional changes in the gastric mucosa, including enterochromaffin-like cell hyperplasia and fundic gland polyps. Evidence indicates that these findings are largely benign and do not warrant specific endoscopic surveillance in most cases.

The association between PPI and gastric cancer was initially suggested in studies published over a decade ago. However, subsequent meta-analyses have questioned these findings, highlighting the potential methodological biases. These include the failure to account for Helicobacter pylori infection, a well-established and independent gastric carcinogen.

Defined Risks, Limited Magnitude

Some adverse effects that are clearly associated with PPI use have been well described. The risk for Clostridioides difficile infection increased modestly, with an odds ratio of 1.74 (95% CI, 1.47-2.85; P < .001). This risk is higher in hospitalized individuals and those receiving concurrent antibiotic therapy.

The association between osteoporosis and fractures is a frequently cited concern. Meta-analyses confirm a small increase in risk, with a relative risk of 1.3 (95% CI, 1.16-1.45). 

However, there is no convincing evidence of a clinically relevant long-term effect of PPI on bone metabolism in humans. These findings suggest that residual confounding factors, such as frailty or advanced age, may account for much of the observed associations.

Concerns regarding the interaction with clopidogrel now appear to be largely resolved. Randomized clinical trials have not shown an increased incidence of cardiovascular events in patients treated with PPI. Pharmacokinetic interactions are primarily limited to omeprazole and can be avoided by using alternative agents such as lansoprazole or rabeprazole.

The Central Issue: Inappropriate Prescribing

The most tangible and clinically relevant risk associated with PPI use is their unnecessary prolonged use. Treatment should be reviewed periodically, particularly after the eradication of H pylori infection or the discontinuation of nonsteroidal anti-inflammatory drugs.

When no clear ongoing indication exists, gradual dose reduction or withdrawal should be considered to minimize the risk for rebound acid hypersecretion following abrupt discontinuation. Deprescribing should not be understood as depriving patients of effective therapies. Rather, it should reflect an ongoing individual assessment of benefits and risks over time.

PPI remains one of the most reliable pillars of digestive therapies. Their introduction has fundamentally altered clinical outcomes, prognosis, and mortality in conditions that, until recently, lacked effective treatment options.

Portraying these drugs as inherently dangerous risks causes more harm than benefit by fostering fear and undermining trust in life-saving interventions.

The priority should not be restriction driven by media alarm, but to ensure that each prescription is clinically justified with an appropriate duration and responsible follow-up.

Conflicts of interest of the authors of the cited studies are available in their original publications.

This story was translated from Univadis Spain, part of the Medscape Professional Network.